Adis, 41 Centorian Drive, Private Bag 65901, Mairangi Bay, North Shore, 0754 Auckland, New Zealand.
BioDrugs. 2013 Aug;27(4):401-6. doi: 10.1007/s40259-013-0037-2.
Canakinumab (Ilaris®), an anti-interleukin-1β monoclonal antibody, is a novel approach to treat acute gouty arthritis flares in a targeted population of patients in whom treatment options are limited. Relative to on-demand treatment with intramuscular triamcinolone acetonide 40 mg, on-demand treatment with subcutaneous canakinumab 150 mg significantly relieved the pain and inflammation of a new gout flare, and reduced the risk of new flares in patients with acute gouty arthritis flares in whom standard treatment with non-steroidal anti-inflammatories and/or colchicine was inappropriate. Canakinumab has an acceptable tolerability profile in this difficult-to-treat population. The increased risk of infections and neutropenia associated with canakinumab treatment can be minimized by following the recommended precautions.
卡那单抗（依拉利司），一种抗白细胞介素-1β的单克隆抗体，是一种针对目标人群中治疗选择有限的急性痛风性关节炎发作的新型治疗方法。与按需肌内注射曲安奈德 40mg 相比，按需皮下注射卡那单抗 150mg 能显著缓解新发痛风发作的疼痛和炎症，并降低非甾体抗炎药和/或秋水仙碱标准治疗不适用的急性痛风性关节炎发作患者新发发作的风险。卡那单抗在这一治疗难度较大的人群中具有可接受的耐受性。通过遵循建议的预防措施，可以最大限度地降低卡那单抗治疗相关感染和中性粒细胞减少的风险。
